Localized Prostate Cancer VL

CEASAR Study Reveals Long-Term Quality of Life Outcomes for Localized Prostate Cancer Treatments - Daniel Barocas & Bashir Al Hussein Al Awamlh

Details
Alicia Morgans hosts Daniel Barocas and Bashir Al Hussein Al Awamlh to discuss findings from the CEASAR study published in JAMA, which explores long-term quality of life outcomes for men with localized prostate cancer. Initiated by Dave Penson, this longitudinal study aims to enhance shared decision-making in treatment by providing data on the side effects of various prostate cancer treatments. Fo...

PSMA PET & The Impact of the PRIMARY Trial "Presentation" - Louise Emmett

Details
At the 2024 PSMA Conference PSMA PET and RLT: Present and Future, Louise Emmett explores enhancing prostate cancer diagnosis with PSMA PET imaging, revealing the PRIMARY trials' findings that combining PSMA PET with MRI significantly improves the accuracy of detecting clinically significant malignancies. Dr. Emmett introduces the PRIMARY score for interpreting PSMA PET results and discusses ongoin...

ProtecT Trial 15-Year Data Shows Low Prostate Cancer Mortality Across Therapies for Localized Disease, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg

Details
Matthew Cooperberg introduces the inaugural patient-oriented journal club for patients diagnosed with prostate cancer. This patient journal club aims to highlight prostate cancer research, selected trials, and pivot to open discussion between expert clinicians and patients. The 15-year update from the ProtecT trial, led by Professors Freddie Hamdy and Jenny Donovan is the selected trial for this s...

Discussion Between Expert Clinicians and Patients on the ProtecT Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg

Details
In this Prostate Cancer Patient Journal Club discussion, Matthew Cooperberg and Jenny Donovan address quality-of-life outcomes from the ProtecT trial's surveillance group. Jenny notes that those who did not progress avoided radical treatment impacts, with no significant quality of life difference compared to radically treated patients. Group discussion includes side effects and global variability...

Radiation Outcomes Improve with Age in Localized Prostate Cancer - Mack Roach

Details
Alicia Morgans talks with Mack Roach about his research in radiation oncology and urology. Dr. Roach discusses his involvement in studies like RTOG 75-06, 86-10, and 85-31, focusing on hormones and radiation in prostate cancer. He shares insights from his analysis of pre-treatment testosterone data from 2,400 patients, revealing that age over 70 correlates with better prostate cancer-specific outc...

How Mental Health Disorders Impact Treatment Decisions in Localized Prostate Cancer - Yaw Nyame & Joshua Cabral

Details
Ruchika Talwar hosts Joshua Cabral and Yaw Nyame to explore the impact of mental health disorders on prostate cancer care. Their study, "Inequities in Definitive Treatment for Localized Prostate Cancer Among Those With Clinically Significant Mental Health Disorders," used the Medicare database from 2004 to 2015. They found that 50% of US adults meet DSM-IV disorder criteria at some point, and ment...

Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg

Details
Zach Klaassen converses with Matthew Cooperberg about findings from the EMBARK study, presented at ESMO and published in the New England Journal. The study focuses on the efficacy of enzalutamide (enza) plus leuprolide versus leuprolide alone in treating high-risk non-metastatic hormone-sensitive prostate cancer. Dr. Cooperberg notes the predictability of better efficacy with combination treatment...

PACE B Study Analysis: Acute and Late Toxicities in Prostate Cancer Radiotherapy - Ragu Ratnakumaran

Details
Phillip Koo interviews Ragu Ratnakumaran about the analysis of the PACE-B study. The study is a phase III international randomized control trial involving 874 patients with low to intermediate-risk prostate cancer. Dr. Ratnakumaran's analysis focuses on the association between acute and late genitourinary and gastrointestinal toxicities in two radiotherapy treatment arms: conventional or moderatel...

The Prognostic Value of PSA Levels Post-Radiation in Prostate Cancer - Praful Ravi

Details
Alicia Morgans interviews Praful Ravi about his abstract presentation concerning PSA nadir within the ICECaP data set. ICECaP, a comprehensive data repository of individual patient data from more than 40 randomized trials conducted in localized prostate cancer, reveals that metastasis-free survival (MFS) is a proven surrogate for overall survival. In their study, Ravi and his team leveraged the IC...

Exploring Regional Variation in Genomic Testing and Imaging in Prostate Cancer - Michael S. Leapman

Details
In an interview with Matthew Cooperberg, Michael Leapman discusses his research on the use of genomic tests and imaging in prostate cancer and the resulting national practice patterns. Leapman found significant regional variation in the utilization of these tests, with areas rich in urologists and prostate cancer care showing higher adoption rates. He also observed a correlation between increased...